In the context of the current COVID-19 pandemic, evidence from the international SECURE-IBD registry of adult and pediatric patients indicates that combination anti-TNF and thiopurine therapy confers a four-fold higher risk of severe COVID-19 above anti-TNF monotherapy, implicating thiopurines as the primary factor in this heightened risk (76). The gene discussed is TNF; the disease is COVID-19.